Targeting key proximal drivers of type 2 inflammation in disease (original) (raw)

• Asher, M. I. et al. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys. Lancet 368, 733–743 (2006).
  Article PubMed Google Scholar
• Pawankar, R., Canonica, G., Holgate, S. & Lockey, R. WAO White Book on Allergy 2011–2012: Executive Summary (World Allergy Organization, 2011).
  Google Scholar
• Prescott, S. L. et al. A global survey of changing patterns of food allergy burden in children. World Allergy Organ. J. 6, 21 (2013).
  Article PubMed PubMed Central Google Scholar
• Kay, A. B. Allergy and allergic diseases. Second of two parts. N. Engl. J. Med. 344, 109–113 (2001).
  Article CAS PubMed Google Scholar
• Kay, A. B. Allergy and allergic diseases. First of two parts. N. Engl. J. Med. 344, 30–37 (2001).
  Article CAS PubMed Google Scholar
• Wynn, T. A. Type 2 cytokines: mechanisms and therapeutic strategies. Nat. Rev. Immunol. 15, 271–282 (2015).
  Article CAS PubMed Google Scholar
• Peebles, R. S. Jr. At the bedside: the emergence of group 2 innate lymphoid cells in human disease. J. Leukoc. Biol. 97, 469–475 (2015).
  Article CAS PubMed Google Scholar
• Leung, D. Y. & Bieber, T. Atopic dermatitis. Lancet 361, 151–160 (2003).
  Article PubMed Google Scholar
• Adcock, I. M., Maneechotesuwan, K. & Usmani, O. Molecular interactions between glucocorticoids and long-acting β2-agonists. J. Allergy Clin. Immunol. 110, S261–S268 (2002).
  Article CAS PubMed Google Scholar
• Haeck, I. M. et al. Enteric-coated mycophenolate sodium versus cyclosporin A as long-term treatment in adult patients with severe atopic dermatitis: a randomized controlled trial. J. Am. Acad. Dermatol. 64, 1074–1084 (2011).
  Article CAS PubMed Google Scholar
• Seale, J. P. & Compton, M. R. Side-effects of corticosteroid agents. Med. J. Aust. 144, 139–142 (1986).
  Article CAS PubMed Google Scholar
• Nesbitt, L. T. Jr. Minimizing complications from systemic glucocorticosteroid use. Dermatol. Clin. 13, 925–939 (1995).
  Article PubMed Google Scholar
• Jacobi, A., Antoni, C., Manger, B., Schuler, G. & Hertl, M. Infliximab in the treatment of moderate to severe atopic dermatitis. J. Am. Acad. Dermatol. 52, 522–526 (2005).
  Article PubMed Google Scholar
• Fahy, J. V. et al. The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects. Am. J. Respir. Crit. Care Med. 155, 1828–1834 (1997).
  Article CAS PubMed Google Scholar
• Busse, W. et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J. Allergy Clin. Immunol. 108, 184–190 (2001).
  Article CAS PubMed Google Scholar
• Soler, M. et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur. Respir. J. 18, 254–261 (2001).
  Article CAS PubMed Google Scholar
• Gevaert, P. et al. Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma. J. Allergy Clin. Immunol. 131, 110–116.e1 (2013).
  Article CAS PubMed Google Scholar
• Maurer, M., Rosen, K. & Hsieh, H. J. Omalizumab for chronic urticaria. N. Engl. J. Med. 368, 2530 (2013).
  Article CAS PubMed Google Scholar
• Saini, S. S. et al. Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study. J. Invest. Dermatol. 135, 925 (2015).
  Article CAS PubMed Google Scholar
• Zuberbier, T. & Maurer, M. Omalizumab for the treatment of chronic urticaria. Expert Rev. Clin. Immunol. 11, 171–180 (2015).
  Article CAS PubMed Google Scholar
• Heil, P. M., Maurer, D., Klein, B., Hultsch, T. & Stingl, G. Omalizumab therapy in atopic dermatitis: depletion of IgE does not improve the clinical course — a randomized, placebo-controlled and double blind pilot study. J. Dtsch. Dermatol. Ges. 8, 990–998 (2010).
  PubMed Google Scholar
• Jeong, C. W. et al. Differential in vivo cytokine mRNA expression in lesional skin of intrinsic versus extrinsic atopic dermatitis patients using semiquantitative RT-PCR. Clin. Exp. Allergy 33, 1717–1724 (2003).
  Article CAS PubMed Google Scholar
• Suárez- Fariñas, M. et al. Intrinsic atopic dermatitis shows similar TH2 and higher TH17 immune activation compared with extrinsic atopic dermatitis. J. Allergy Clin. Immunol. 132, 361–370 (2013).
  Article CAS Google Scholar
• Akdis, C. A. & Akdis, M. Immunological differences between intrinsic and extrinsic types of atopic dermatitis. Clin. Exp. Allergy 33, 1618–1621 (2003).
  Article CAS PubMed Google Scholar
• Ying, S. et al. Expression of _IL_-4 and _IL_-5 mRNA and protein product by CD4+ and CD8+ T cells, eosinophils, and mast cells in bronchial biopsies obtained from atopic and nonatopic (intrinsic) asthmatics. J. Immunol. 158, 3539–3544 (1997).
  CAS PubMed Google Scholar
• Green, R. H. et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet 360, 1715–1721 (2002).
  Article PubMed Google Scholar
• Bentley, A. M. et al. Identification of T lymphocytes, macrophages, and activated eosinophils in the bronchial mucosa in intrinsic asthma. Relationship to symptoms and bronchial responsiveness. Am. Rev. Respir. Dis. 146, 500–506 (1992).
  Article CAS PubMed Google Scholar
• Gittler, J. K. et al. Progressive activation of TH2/TH22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis. J. Allergy Clin. Immunol. 130, 1344–1354 (2012). This study elucidated the molecular factors of acute and chronic atopic dermatitis lesions as a progressive activation of T H 2 and T H 22 immune axes rather than biphasic response predominating in T H 2 in acute lesion and a switch to T H 1 in chronic disease.
  Article CAS PubMed PubMed Central Google Scholar
• Hamid, Q., Boguniewicz, M. & Leung, D. Y. Differential in situ cytokine gene expression in acute versus chronic atopic dermatitis. J. Clin. Invest. 94, 870–876 (1994).
  Article CAS PubMed PubMed Central Google Scholar
• Grewe, M. et al. Analysis of the cytokine pattern expressed in situ in inhalant allergen patch test reactions of atopic dermatitis patients. J. Invest. Dermatol. 105, 407–410 (1995).
  Article CAS PubMed Google Scholar
• Pacor, M. L. et al. Comparing tacrolimus ointment and oral cyclosporine in adult patients affected by atopic dermatitis: a randomized study. Clin. Exp. Allergy 34, 639–645 (2004).
  Article CAS PubMed Google Scholar
• Suárez- Fariñas, M. et al. Nonlesional atopic dermatitis skin is characterized by broad terminal differentiation defects and variable immune abnormalities. J. Allergy Clin. Immunol. 127, 954–964.e4 (2011). This study found that non-lesional skin of patients with atopic dermatitis is distinct from skin of healthy patients, indicative of systemic immune activation in patients with atopic dermatitis.
  Article Google Scholar
• Kakinuma, T. et al. Thymus and activation-regulated chemokine in atopic dermatitis: serum thymus and activation-regulated chemokine level is closely related with disease activity. J. Allergy Clin. Immunol. 107, 535–541 (2001).
  Article CAS PubMed Google Scholar
• Hijnen, D. et al. Serum thymus and activation-regulated chemokine (TARC) and cutaneous T cell- attracting chemokine (CTACK) levels in allergic diseases: TARC and CTACK are disease-specific markers for atopic dermatitis. J. Allergy Clin. Immunol. 113, 334–340 (2004).
  Article CAS PubMed Google Scholar
• Jahnz-Rozyk, K., Targowski, T., Paluchowska, E., Owczarek, W. & Kucharczyk, A. Serum thymus and activation-regulated chemokine, macrophage-derived chemokine and eotaxin as markers of severity of atopic dermatitis. Allergy 60, 685–688 (2005).
  Article CAS PubMed Google Scholar
• Imai, T. et al. The T cell-directed CC chemokine TARC is a highly specific biological ligand for CC chemokine receptor 4. J. Biol. Chem. 272, 15036–15042 (1997).
  Article CAS PubMed Google Scholar
• van Drunen, C. M., Reinartz, S., Wigman, J. & Fokkens, W. J. Inflammation in chronic rhinosinusitis and nasal polyposis. Immunol. Allergy Clin. North Am. 29, 621–629 (2009).
  Article PubMed Google Scholar
• Meltzer, E. O. et al. Rhinosinusitis: establishing definitions for clinical research and patient care. J. Allergy Clin. Immunol. 114, 155–212 (2004).
  Article PubMed PubMed Central Google Scholar
• Van Zele, T. et al. Differentiation of chronic sinus diseases by measurement of inflammatory mediators. Allergy 61, 1280–1289 (2006).
  Article CAS PubMed Google Scholar
• Van Cauwenberge, P., Van Hoecke, H. & Bachert, C. Pathogenesis of chronic rhinosinusitis. Curr. Allergy Asthma Rep. 6, 487–494 (2006).
  Article CAS PubMed Google Scholar
• Aouad, R. K. & Chiu, A. G. State of the art treatment of nasal polyposis. Am. J. Rhinol. Allergy 25, 291–298 (2011).
  Article PubMed Google Scholar
• Noben-Trauth, N. et al. An interleukin 4 (IL-4)-independent pathway for CD4+ T cell IL-4 production is revealed in IL-4 receptor-deficient mice. Proc. Natl Acad. Sci. USA 94, 10838–10843 (1997).
  Article CAS PubMed PubMed Central Google Scholar
• Kopf, M. et al. Disruption of the murine _IL_-4 gene blocks TH2 cytokine responses. Nature 362, 245–248 (1993).
  Article CAS PubMed Google Scholar
• Barner, M., Mohrs, M., Brombacher, F. & Kopf, M. Differences between IL-4Rα-deficient and IL-4-deficient mice reveal a role for IL-13 in the regulation of Th2 responses. Curr. Biol. 8, 669–672 (1998).
  Article CAS PubMed Google Scholar
• Liddiard, K. et al. Interleukin-4 induction of the CC chemokine TARC (CCL17) in murine macrophages is mediated by multiple STAT6 sites in the TARC gene promoter. BMC Mol. Biol. 7, 45 (2006).
  Article PubMed CAS PubMed Central Google Scholar
• Wirnsberger, G., Hebenstreit, D., Posselt, G., Horejs-Hoeck, J. & Duschl, A. IL-4 induces expression of TARC/CCL17 via two STAT6 binding sites. Eur. J. Immunol. 36, 1882–1891 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Mochizuki, M., Bartels, J., Mallet, A. I., Christophers, E. & Schroder, J. M. IL-4 induces eotaxin: a possible mechanism of selective eosinophil recruitment in helminth infection and atopy. J. Immunol. 160, 60–68 (1998).
  CAS PubMed Google Scholar
• Hoeck, J. & Woisetschlager, M. STAT6 mediates eotaxin-1 expression in IL-4 or TNF-α-induced fibroblasts. J. Immunol. 166, 4507–4515 (2001).
  Article CAS PubMed Google Scholar
• Swain, S. L., Weinberg, A. D., English, M. & Huston, G. IL-4 directs the development of Th2-like helper effectors. J. Immunol. 145, 3796–3806 (1990).
  CAS PubMed Google Scholar
• Lazarski, C. A., Ford, J., Katzman, S. D., Rosenberg, A. F. & Fowell, D. J. IL-4 attenuates Th1-associated chemokine expression and Th1 trafficking to inflamed tissues and limits pathogen clearance. PLoS ONE 8, e71949 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Wagner, F., Fischer, N., Lersch, C., Hart, R. & Dancygier, H. Interleukin 4 inhibits the interleukin 2-induced production of its functional antagonist, interferon γ. Immunol. Lett. 21, 237–241 (1989).
  Article CAS PubMed Google Scholar
• Van Dyken, S. J. & Locksley, R. M. Interleukin-4- and interleukin-13-mediated alternatively activated macrophages: roles in homeostasis and disease. Annu. Rev. Immunol. 31, 317–343 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Hershey, G. K. IL-13 receptors and signaling pathways: an evolving web. J. Allergy Clin. Immunol. 111, 677–690 (2003).
  Article CAS PubMed Google Scholar
• Akaiwa, M. et al. Localization of human interleukin 13 receptor in non-haematopoietic cells. Cytokine 13, 75–84 (2001).
  Article CAS PubMed Google Scholar
• McKenzie, G. J., Fallon, P. G., Emson, C. L., Grencis, R. K. & McKenzie, A. N. Simultaneous disruption of interleukin (IL)-4 and IL-13 defines individual roles in T helper cell type 2-mediated responses. J. Exp. Med. 189, 1565–1572 (1999).
  Article CAS PubMed PubMed Central Google Scholar
• LaPorte, S. L. et al. Molecular and structural basis of cytokine receptor pleiotropy in the interleukin-4/13 system. Cell 132, 259–272 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Laporte, J. C. et al. Direct effects of interleukin-13 on signaling pathways for physiological responses in cultured human airway smooth muscle cells. Am. J. Respir. Crit. Care Med. 164, 141–148 (2001).
  Article CAS PubMed Google Scholar
• Chatila, T. A. Interleukin-4 receptor signaling pathways in asthma pathogenesis. Trends Mol. Med. 10, 493–499 (2004).
  Article CAS PubMed Google Scholar
• Finkelman, F. D. et al. Suppression of in vivo polyclonal IgE responses by monoclonal antibody to the lymphokine B-cell stimulatory factor 1. Proc. Natl Acad. Sci. USA 83, 9675–9678 (1986).
  Article CAS PubMed PubMed Central Google Scholar
• Finkelman, F. D. et al. Regulation of murine in vivo IgG and IgE responses by a monoclonal anti-IL-4 receptor antibody. Int. Immunol. 3, 599–607 (1991).
  Article CAS PubMed Google Scholar
• Grunewald, S. M. et al. An antagonistic IL-4 mutant prevents type I allergy in the mouse: inhibition of the IL-4/IL-13 receptor system completely abrogates humoral immune response to allergen and development of allergic symptoms in vivo. J. Immunol. 160, 4004–4009 (1998).
  CAS PubMed Google Scholar
• McKenzie, G. J. et al. Impaired development of Th2 cells in IL-13-deficient mice. Immunity 9, 423–432 (1998).
  Article CAS PubMed Google Scholar
• Mohrs, M. et al. Differences between IL-4- and IL-4 receptor α-deficient mice in chronic leishmaniasis reveal a protective role for IL-13 receptor signaling. J. Immunol. 162, 7302–7308 (1999).
  CAS PubMed Google Scholar
• Ogata, H. et al. Regulation of interleukin-13 receptor constituents on mature human B lymphocytes. J. Biol. Chem. 273, 9864–9871 (1998).
  Article CAS PubMed Google Scholar
• Kouro, T. & Takatsu, K. IL-5- and eosinophil-mediated inflammation: from discovery to therapy. Int. Immunol. 21, 1303–1309 (2009).
  Article CAS PubMed Google Scholar
• Yamada, T. et al. IL-3, IL-5, granulocyte–macrophage colony- stimulating factor receptor α-subunit, and common β-subunit expression by peripheral leukocytes and blood dendritic cells. J. Allergy Clin. Immunol. 101, 677–682 (1998).
  Article CAS PubMed Google Scholar
• Foster, P. S., Hogan, S. P., Ramsay, A. J., Matthaei, K. I. & Young, I. G. Interleukin 5 deficiency abolishes eosinophilia, airways hyperreactivity, and lung damage in a mouse asthma model. J. Exp. Med. 183, 195–201 (1996).
  Article CAS PubMed Google Scholar
• Busse, W. W., Ring, J., Huss-Marp, J. & Kahn, J. E. A review of treatment with mepolizumab, an anti-IL-5 mAb, in hypereosinophilic syndromes and asthma. J. Allergy Clin. Immunol. 125, 803–813 (2010).
  Article CAS PubMed Google Scholar
• Moqbel, R. & Odemuyiwa, S. O. Allergy, asthma, and inflammation: which inflammatory cell type is more important? Allergy Asthma Clin. Immunol. 4, 150–156 (2008).
  Article PubMed PubMed Central Google Scholar
• Webb, D. C. et al. Integrated signals between IL-13, IL-4, and IL-5 regulate airways hyperreactivity. J. Immunol. 165, 108–113 (2000).
  Article CAS PubMed Google Scholar
• Rosenberg, H. F., Phipps, S. & Foster, P. S. Eosinophil trafficking in allergy and asthma. J. Allergy Clin. Immunol. 119, 1303–1310 (2007).
  Article CAS PubMed Google Scholar
• Gavett, S. H. et al. Interleukin-4 receptor blockade prevents airway responses induced by antigen challenge in mice. Am. J. Physiol. 272, L253–L261 (1997).
  CAS PubMed Google Scholar
• Brusselle, G. G. et al. Attenuation of allergic airway inflammation in IL-4 deficient mice. Clin. Exp. Allergy 24, 73–80 (1994).
  Article CAS PubMed Google Scholar
• Walter, D. M. et al. Critical role for IL-13 in the development of allergen-induced airway hyperreactivity. J. Immunol. 167, 4668–4675 (2001).
  Article CAS PubMed Google Scholar
• Cockcroft, D. W. & Davis, B. E. Mechanisms of airway hyperresponsiveness. J. Allergy Clin. Immunol. 118, 551–559 (2006).
  Article CAS PubMed Google Scholar
• Katial, R. K. & Covar, R. A. Bronchoprovocation testing in asthma. Immunol. Allergy Clin. North Am. 32, 413–431 (2012).
  Article PubMed Google Scholar
• Grunig, G. et al. Requirement for IL-13 independently of IL-4 in experimental asthma. Science 282, 2261–2263 (1998).
  Article CAS PubMed PubMed Central Google Scholar
• Wills-Karp, M. et al. Interleukin-13: central mediator of allergic asthma. Science 282, 2258–2261 (1998).
  Article CAS PubMed Google Scholar
• Komai, M. et al. Role of Th2 responses in the development of allergen-induced airway remodelling in a murine model of allergic asthma. Br. J. Pharmacol. 138, 912–920 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Zhu, Z. et al. Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production. J. Clin. Invest. 103, 779–788 (1999).
  Article CAS PubMed PubMed Central Google Scholar
• Chu, H. W. et al. Collagen deposition in large airways may not differentiate severe asthma from milder forms of the disease. Am. J. Respir. Crit. Care Med. 158, 1936–1944 (1998).
  Article CAS PubMed Google Scholar
• Kanoh, S., Tanabe, T. & Rubin, B. K. IL-13-induced MUC5AC production and goblet cell differentiation is steroid resistant in human airway cells. Clin. Exp. Allergy 41, 1747–1756 (2011).
  Article CAS PubMed Google Scholar
• Kurowska-Stolarska, M. et al. IL-33 induces antigen-specific IL-5+ T cells and promotes allergic-induced airway inflammation independent of IL-4. J. Immunol. 181, 4780–4790 (2008).
  Article CAS PubMed Google Scholar
• Li, Y. L. et al. Thymic stromal lymphopoietin promotes lung inflammation through activation of dendritic cells. J. Asthma 47, 117–123 (2010).
  Article CAS PubMed Google Scholar
• Lee, G. R. & Flavell, R. A. Transgenic mice which overproduce Th2 cytokines develop spontaneous atopic dermatitis and asthma. Int. Immunol. 16, 1155–1160 (2004).
  Article CAS PubMed Google Scholar
• Zheng, T. et al. Transgenic expression of interleukin-13 in the skin induces a pruritic dermatitis and skin remodeling. J. Invest. Dermatol. 129, 742–751 (2009).
  Article CAS PubMed Google Scholar
• Rankin, J. A. et al. Phenotypic and physiologic characterization of transgenic mice expressing interleukin 4 in the lung: lymphocytic and eosinophilic inflammation without airway hyperreactivity. Proc. Natl Acad. Sci. USA 93, 7821–7825 (1996).
  Article CAS PubMed PubMed Central Google Scholar
• Chan, L. S., Robinson, N. & Xu, L. Expression of interleukin-4 in the epidermis of transgenic mice results in a pruritic inflammatory skin disease: an experimental animal model to study atopic dermatitis. J. Invest. Dermatol. 117, 977–983 (2001).
  Article CAS PubMed Google Scholar
• Buttner, C., Lun, A., Splettstoesser, T., Kunkel, G. & Renz, H. Monoclonal anti-interleukin-5 treatment suppresses eosinophil but not T-cell functions. Eur. Respir. J. 21, 799–803 (2003).
  Article CAS PubMed Google Scholar
• Flood-Page, P. et al. A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. Am. J. Respir. Crit. Care Med. 176, 1062–1071 (2007).
  Article CAS PubMed Google Scholar
• Leckie, M. J. et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 356, 2144–2148 (2000).
  Article CAS PubMed Google Scholar
• Oldhoff, J. M. et al. No effect of anti-interleukin-5 therapy (mepolizumab) on the atopy patch test in atopic dermatitis patients. Int. Arch. Allergy Immunol. 141, 290–294 (2006).
  Article CAS PubMed Google Scholar
• Barnes, P. J. Cytokine-directed therapies for the treatment of chronic airway diseases. Cytokine Growth Factor Rev. 14, 511–522 (2003).
  Article CAS PubMed Google Scholar
• Oldhoff, J. M. et al. Anti-IL-5 recombinant humanized monoclonal antibody (mepolizumab) for the treatment of atopic dermatitis. Allergy 60, 693–696 (2005).
  Article CAS PubMed Google Scholar
• Borish, L. C. et al. Efficacy of soluble IL-4 receptor for the treatment of adults with asthma. J. Allergy Clin. Immunol. 107, 963–970 (2001).
  Article CAS PubMed Google Scholar
• Borish, L. C. et al. Interleukin-4 receptor in moderate atopic asthma. A phase I/II randomized, placebo-controlled trial. Am. J. Respir. Crit. Care Med. 160, 1816–1823 (1999).
  Article CAS PubMed Google Scholar
• Gauvreau, G. M. et al. The effects of IL-13 blockade on allergen-induced airway responses in mild atopic asthma. Am. J. Respir. Crit. Care Med. 183, 1007–1014 (2010).
  Article PubMed CAS Google Scholar
• Maes, T., Joos, G. F. & Brusselle, G. G. Targeting interleukin-4 in asthma: lost in translation? Am. J. Respir. Cell. Mol. Biol. 47, 261–270 (2012).
  Article CAS PubMed Google Scholar
• Oh, C. K., Geba, G. P. & Molfino, N. Investigational therapeutics targeting the IL-4/IL-13/STAT-6 pathway for the treatment of asthma. Eur. Respir. Rev. 19, 46–54 (2010).
  Article CAS PubMed Google Scholar
• Economides, A. N. et al. Cytokine traps: multi-component, high-affinity blockers of cytokine action. Nat. Med. 9, 47–52 (2003).
  Article CAS PubMed Google Scholar
• Wenzel, S., Wilbraham, D., Fuller, R., Getz, E. B. & Longphre, M. Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies. Lancet 370, 1422–1431 (2007).
  Article CAS PubMed Google Scholar
• Groves, R. W., Wilbraham, D., Fuller, R. & Longphre, M. Inhibition of IL-4 and IL-13 with an IL-4 mutein (Aeroderm) protects against flares in atopic eczema. J. Invest. Dermatol. 127, S54 (2007).
  Google Scholar
• Corren, J. et al. A randomized, controlled, phase 2 study of AMG 317, an IL-4Rα antagonist, in patients with asthma. Am. J. Respir. Crit. Care Med. 181, 788–796 (2010).
  Article CAS PubMed Google Scholar
• Kakkar, T. et al. Population PK and IgE pharmacodynamic analysis of a fully human monoclonal antibody against IL4 receptor. Pharm. Res. 28, 2530–2542 (2011).
  Article CAS PubMed Google Scholar
• Wenzel, S. E. Asthma: defining of the persistent adult phenotypes. Lancet 368, 804–813 (2006).
  Article CAS PubMed Google Scholar
• Haldar, P. et al. Cluster analysis and clinical asthma phenotypes. Am. J. Respir. Crit. Care Med. 178, 218–224 (2008).
  Article PubMed Google Scholar
• Moore, W. C. et al. Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. Am. J. Respir. Crit. Care Med. 181, 315–323 (2010).
  Article PubMed Google Scholar
• Haldar, P. et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N. Engl. J. Med. 360, 973–984 (2009). This is one of two studies demonstrating the efficacy of IL-5 blockade in patients with high numbers of eosinophils in sputum.
  Article CAS PubMed PubMed Central Google Scholar
• Fahy, J. V. Eosinophilic and neutrophilic inflammation in asthma: insights from clinical studies. Proc. Am. Thorac Soc. 6, 256–259 (2009).
  Article CAS PubMed Google Scholar
• Takayama, G. et al. Periostin: a novel component of subepithelial fibrosis of bronchial asthma downstream of IL-4 and IL-13 signals. J. Allergy Clin. Immunol. 118, 98–104 (2006).
  Article CAS PubMed Google Scholar
• Woodruff, P. G. et al. T-helper type 2-driven inflammation defines major subphenotypes of asthma. Am. J. Respir. Crit. Care Med. 180, 388–395 (2009). These authors show that there are two distinct molecular subgroups of asthma, suggesting that some therapeutic targets may only be relevant in subsets of patients with asthma.
  Article CAS PubMed PubMed Central Google Scholar
• Nair, P. et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N. Engl. J. Med. 360, 985–993 (2009).
  Article CAS PubMed Google Scholar
• Pavord, I. D. et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 380, 651–659 (2012).
  Article CAS PubMed Google Scholar
• Ortega, H. G. et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N. Engl. J. Med. 371, 1198–1207 (2014).
  Article CAS PubMed Google Scholar
• Ultsch, M. et al. Structural basis of signaling blockade by anti-IL-13 antibody lebrikizumab. J. Mol. Biol. 425, 1330–1339 (2013).
  Article CAS PubMed Google Scholar
• Scheerens, H. et al. The effects of lebrikizumab in patients with mild asthma following whole lung allergen challenge. Clin. Exp. Allergy 44, 38–46 (2014).
  Article CAS PubMed Google Scholar
• Corren, J. et al. Lebrikizumab treatment in adults with asthma. N. Engl. J. Med. 365, 1088–1098 (2011). This study demonstrates the efficacy of anti-IL-13 treatment on lung function and that this therapy is more effective in patients with a biomarker profile of T H 2-type activity.
  Article CAS PubMed Google Scholar
• Noonan, M. et al. Dose-ranging study of lebrikizumab in asthmatic patients not receiving inhaled steroids. J. Allergy Clin. Immunol. 132, 567–574.e12 (2013).
  Article CAS PubMed Google Scholar
• Wenzel, S. E. et al. Inhaled pitrakinra, an IL-4/IL-13 antagonist, reduced exacerbations in patients with eosinophilic asthma. Eur. Respir. J. 36 (Suppl. 54), 713s (2010).
  Google Scholar
• Juniper, E. F., Svensson, K., Mork, A. C. & Stahl, E. Measurement properties and interpretation of three shortened versions of the asthma control questionnaire. Respir. Med. 99, 553–558 (2005).
  Article PubMed Google Scholar
• Wenzel, S. et al. Dupilumab in persistent asthma with elevated eosinophil levels. N. Engl. J. Med. 368, 2455–2466 (2013). This is a proof-of-concept study demonstrating the efficacy of simultaneous blockade of IL-4 and IL-13 in asthmatics with high numbers of eosinophils in blood.
  Article CAS PubMed Google Scholar
• Wenzel, S. et al. Dupilumab improves lung function and reduces severe exacerbations in uncontrolled asthmatics with baseline eosinophil levels above and below 300 cells/μl. Am. J. Respir. Crit. Care Med. 191, A3632 (2015).
  Google Scholar
• Chase, E. P. & Armstrong, A. W. Advances in management of atopic dermatitis: new therapies and novel uses of existing treatments. Semin. Cutan Med. Surg. 31, 17–24 (2012).
  Article CAS PubMed Google Scholar
• Ong, P. Y. Emerging drugs for atopic dermatitis. Expert Opin. Emerg. Drugs 14, 165–179 (2009).
  Article CAS PubMed Google Scholar
• Radin, A., R. H., Papino-Wood, P., Chaudhry, U. & Hamilton, J. D. First-in-human study of REGN668/SAR231893 (IL-4Rα mAb): safety, tolerability and biomarker results of a randomized, double-blind, placebo-controlled, single ascending dose study in healthy volunteers. J. Allergy Clin. Immunol. 131, SAB158 (2013).
  Article Google Scholar
• Beck, L. A. et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N. Engl. J. Med. 371, 130–139 (2014). This publication reports four clinical studies demonstrating that simultaneous blockade of IL-4 and IL-13 leads to clinical efficacy in atopic dermatitis.
  Article PubMed CAS Google Scholar
• Kam, J. C., Szefler, S. J., Surs, W., Sher, E. R. & Leung, D. Y. Combination IL-2 and IL-4 reduces glucocorticoid receptor-binding affinity and T cell response to glucocorticoids. J. Immunol. 151, 3460–3466 (1993).
  CAS PubMed Google Scholar
• Leung, D. Y. et al. Association of glucocorticoid insensitivity with increased expression of glucocorticoid receptor β. J. Exp. Med. 186, 1567–1574 (1997).
  Article CAS PubMed PubMed Central Google Scholar
• Hamilton, J. D. et al. Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis. J. Allergy Clin. Immunol. 134, 1293–1300 (2014).
  Article CAS PubMed Google Scholar
• Fokkens, W. J. et al. EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists. Rhinology 50, 1–12 (2012).
  Article PubMed Google Scholar
• Van Zele, T. et al. Oral steroids and doxycycline: two different approaches to treat nasal polyps. J. Allergy Clin. Immunol. 125, 1069–1076.e4 (2010).
  Article CAS PubMed Google Scholar
• Pinto, J. M. et al. A randomized, double-blind, placebo-controlled trial of anti-IgE for chronic rhinosinusitis. Rhinology 48, 318–324 (2010).
  Article CAS PubMed Google Scholar
• Gevaert, P. et al. Nasal IL-5 levels determine the response to anti-IL-5 treatment in patients with nasal polyps. J. Allergy Clin. Immunol. 118, 1133–1141 (2006).
  Article CAS PubMed Google Scholar
• Bachert, C. et al. Dupilumab in chronic sinusitis with nasal polyposis, with and without asthma. EAACI Online Library [online], (2015).
  Google Scholar
• Stalder, J. F. & Taïeb, A. Severity scoring of atopic dermatitis: the SCORAD index. Consensus report of the European Task Force on Atopic Dermatitis. Dermatology 186, 23–31 (1993).
  Article Google Scholar
• Haeck, I. M. et al. Moderate correlation between quality of life and disease activity in adult patients with atopic dermatitis. J. Eur. Acad. Dermatol. Venereol. 26, 236–241 (2012).
  Article CAS PubMed Google Scholar
• Hanifin, J. M. et al. The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. Exp. Dermatol. 10, 11–18 (2001).
  Article CAS PubMed Google Scholar
• Barbier, N. et al. Validation of the Eczema Area and Severity Index for atopic dermatitis in a cohort of 1550 patients from the pimecrolimus cream 1% randomized controlled clinical trials programme. Br. J. Dermatol. 150, 96–102 (2004).
  Article CAS PubMed Google Scholar
• Phan, N. Q. et al. Assessment of pruritus intensity: prospective study on validity and reliability of the visual analogue scale, numerical rating scale and verbal rating scale in 471 patients with chronic pruritus. Acta Derm. Venereol. 92, 502–507 (2012).
  Article PubMed Google Scholar
• Berger, W. E. et al. Efficacy and safety evaluation of ciclesonide in subjects with mild-to-moderate asthma not currently using inhaled corticosteroids. Allergy Asthma Proc. 30, 304–314 (2009).
  Article CAS PubMed Google Scholar
• Noonan, M. J. et al. Montelukast, a potent leukotriene receptor antagonist, causes dose-related improvements in chronic asthma. Eur. Respir. J. 11, 1232–1239 (1998).
  Article CAS PubMed Google Scholar
• Cockcroft, D. W. Direct challenge tests: airway hyperresponsiveness in asthma: its measurement and clinical significance. Chest 138, 18S–24S (2010).
  Article CAS PubMed Google Scholar
• Juniper, E. F., Bousquet, J., Abetz, L. & Bateman, E. D. Identifying 'well-controlled' and 'not well-controlled' asthma using the Asthma Control Questionnaire. Respir. Med. 100, 616–621 (2006).
  Article PubMed Google Scholar
• Juniper, E. F., O'Byrne, P. M., Guyatt, G. H., Ferrie, P. J. & King, D. R. Development and validation of a questionnaire to measure asthma control. Eur. Respir. J. 14, 902–907 (1999).
  Article CAS PubMed Google Scholar
• Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention (Global Initiative for Asthma, 2015).
• Diamant, Z., Boot, D., Kamerling, I. & Bjermer, L. Methods used in clinical development of novel anti-asthma therapies. Respir. Med. 102, 332–338 (2008).
  Article PubMed Google Scholar
• Kaiser, J. Medical Officer's Efficacy Review, Genentech, Omalizumab BLA STN 103976/0. US Food and Drug Administration [online], (2003).
  Google Scholar
• Gevaert, P. et al. Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis. J. Allergy Clin. Immunol. 128, 989–995.e8 (2011). This clinical study shows that anti-IL-5 treatment is effective in reducing nasal polyps after two single intravenous injections of mepolizumab.
  Article CAS PubMed Google Scholar
• Groves, R., Wilbrahams, D., Fuller, R. & Longphre, M. Inhibition of IL-4 and IL-13 with an IL-4 mutein (Aeroderm) protects against flares in atopic eczema. J. Invest. Dermatol. 127 (Suppl. 1s), S54 (2007).
  Google Scholar